BD Continues Strong Shareholder Returns with 54th Annual Dividend Increase

BD, short for Becton, Dickinson and Company, has recently announced a quarterly dividend of $1.05 per common share, an increase of 1.0% over the previous quarter. This marks the 54th consecutive year that the company has raised its dividend, solidifying its status among the S&P 500 Dividend Aristocrats. The dividend will be payable on December 31, 2025, to shareholders recorded as of December 8, 2025. This translates to an annual dividend rate of $4.20 per share for the fiscal year 2026.

In a statement, Tom Polen, who serves as the chairman, CEO, and president of BD, expressed pride in the company's sustained commitment to returning value to shareholders. He stated, "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years." He further emphasized that this modest increase reflects not only the company’s healthy financial outlook but also its commitment to delivering value and capital returns.

The decision to increase dividends comes at a time when BD is preparing for significant transitions, including the execution of the Waters RMT transaction. Polen assured stakeholders that the company's management remains optimistic about future growth and profitability, stating that the increase correlates with their long-term strategic vision.

BD is recognized as one of the largest global medical technology firms, actively contributing to advancements in health care through improved medical discovery, diagnostics, and the delivery of care. Leveraging a workforce of over 70,000 employees, the company prioritizes safety and efficiency in clinical care delivery, enhancing capabilities for laboratory scientists to accurately diagnose diseases and enabling researchers to innovate for future treatments.

In alignment with this dedication, BD collaborates with various organizations across the globe, addressing pressing health challenges and striving to improve health outcomes. By enhancing clinical processes, reducing costs while maximizing safety, BD plays a crucial role on the healthcare frontlines.

Understanding the company's role in healthcare, it becomes apparent the significance of maintaining dependable dividend payments for investors who value stability and commitment in their portfolios. BD’s success is built on the pride of its employees and leaders, showcasing a marriage of innovation, responsibility, and long-term growth strategies.

As we move forward into fiscal 2026, BD continues to lead with decisiveness and foresight. This consistent growth in dividends exemplifies a robust organizational health that is beneficial for both stakeholders and the communities it serves. As BD moves on with its transformative initiatives, it remains a staunch supporter of healthcare professionals and researchers, ensuring their critical work is unfaltering in the face of global health challenges.

For those interested in learning more about BD’s journey, their innovative approach can be further explored on their official site or via their LinkedIn and Twitter channels. BD's strategic direction, grounded in a solid foundation of growth and societal contribution, builds confidence as we witness its remarkable journey into the future.